更新于：2024-06-24
Rebamipide
雷巴米特
更新于：2024-06-24
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1990-09-28), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C19H15ClN2O4 |
InChIKeyALLWOAVDORUJLA-UHFFFAOYSA-N |
CAS号90098-04-7 |
关联
142
项与 雷巴米特 相关的临床试验浙江大冢制药有限公司生产的瑞巴派特片（商品名：膜固思达®）与原研药瑞巴派特片（商品名：Mucosta®）在中国健康受试者空腹和餐后状态下的单中心、随机、开放、两制剂、两周期、两序列、单次给药、双交叉生物等效性研究
Randomized, controlled, multicenter clinical study of rebamipide in the prevention of gout attack
Rebamipide as an Adjunct to Methotrexate in Patients With Active Rheumatoid Arthritis
100 项与 雷巴米特 相关的临床结果
登录后查看更多信息
100 项与 雷巴米特 相关的转化医学
登录后查看更多信息
100 项与 雷巴米特 相关的专利（医药）
登录后查看更多信息
640
项与 雷巴米特 相关的文献（医药）Journal of magnetic resonance imaging : JMRI
Reference Values for Water‐Specific T1 of the Liver at 3 T : T2*‐Compensation and the Confounding Effects of Fat
Article
作者: Sherrington, Rachel ; Seres, Peter ; Grenier, Justin ; Beaulieu, Christian ; Thompson, Richard B ; Paterson, David I ; Kirkham, Amy
Background:
T1 mapping of the liver is confounded by the presence of fat. Multiparametric T1 mapping combines fat‐water separation with T1‐weighting to enable imaging of water‐specific T1 (T1Water), proton density fat fraction (PDFF), and T2* values. However, normative T1Water values in the liver and its dependence on age/sex is unknown.
Purpose:
Determine normative values for T1Water in the liver with comparison to MOLLI and evaluate a T2*‐compensation approach to reduce T1 variability.
Study Type:
Prospective observational; phantoms.
Populations:
One hundred twenty‐four controls (56 male, 18–75 years), 50 patients at‐risk for liver disease (18 male, 30–76 years).
Field Strength/Sequence:
2.89 T; Saturation‐recovery chemical‐shift encoded T1 Mapping (SR‐CSE); MOLLI.
Assessment:
SR‐CSE provided T1Water measurements, PDFF and T2* values in the liver across three slices in 6 seconds. These were compared with MOLLI T1 values. A new T2*‐compensation approach to reduce T1 variability was evaluated test/re‐test reproducibility.
Statistical Tests:
Linear regression, ANCOVA, t‐test, Bland and Altman, intraclass correlation coefficient (ICC). P < 0.05 was considered statistically significant.
Results:
Liver T1 values were significantly higher in healthy females (F) than males (M) for both SR‐CSE (F‐973 ± 78 msec, M‐930 ± 72 msec) and MOLLI (F‐802 ± 55 msec, M‐759 ± 69 msec). T1 values were negatively correlated with age, with similar sex‐ and age‐dependencies observed in T2*. The T2*‐compensation model reduced the variability of T1 values by half and removed sex‐ and age‐differences (SR‐CSE: F‐946 ± 36 msec, M‐941 ± 43 msec; MOLLI: F‐775 ± 35 msec, M‐770 ± 35 msec). At‐risk participants had elevated PDFF and T1 values, which became more distinct from the healthy cohort after T2*‐compensation. MOLLI systematically underestimated liver T1 values by ~170 msec with an additional positive T1‐bias from fat content (~11 msec/1% in PDFF). Reproducibility ICC values were ≥0.96 for all parameters.
Data Conclusion:
Liver T1Water values were lower in males and decreased with age, as observed for SR‐CSE and MOLLI acquisitions. MOLLI underestimated liver T1 with an additional large positive fat‐modulated T1 bias. T2*‐compensation removed sex‐ and age‐dependence in liver T1, reduced the range of healthy values and increased T1 group differences between healthy and at‐risk groups.
Evidence Level:
2
Technical Efficacy:
Stage 1
PloS one
Retraction: Rebamipide Promotes the Regeneration of Aspirin-Induced Small-Intestine Mucosal Injury through Accumulation of β-Catenin
2023-11-01Journal of clinical epidemiology
Bayesian structural time series, an alternative to interrupted time series in the right circumstances
Article
作者: Blogg, Suzanne ; Gianacas, Christopher ; Belcher, Josephine ; Muscatello, David J ; Liu, Bette ; Kirk, Martyn ; Di Tanna, Gian Luca
OBJECTIVES:
Compare two approaches to analyzing time series data-interrupted time series with segmented regression (ITS-SR) and Bayesian structural time series using the CausalImpact R package (BSTS-CI)-highlighting advantages, disadvantages, and implementation considerations.
STUDY DESIGN AND SETTING:
We analyzed electronic health records using each approach to estimate the antibiotic prescribing reduction associated with an educational program delivered to Australian primary care physicians between 2012 and 2017. Two outcomes were considered: antibiotics for upper respiratory tract infections (URTIs) and antibiotics of specified formulations.
RESULTS:
For URTI indication prescribing, average monthly prescriptions changes were estimated at -4,550; (95% confidence interval, -5,486 to -3,614) and -4,270; (95% credible interval, -5,934 to -2,626) for ITS-SR and BSTS-CI, respectively. Similarly for specified formulation prescribing, monthly average changes were estimated at -7,923; (95% confidence interval, -15,887 to 40) for ITS-SR and -20,269; (95% credible interval, -25,011 to -15,635) for BSTS-CI.
CONCLUSION:
Differing results between ITS-SR and BSTS-CI appear driven by divergent explanatory and outcome series trends. The BSTS-CI may be a suitable alternative to ITS-SR only if the explanatory series represent the secular trend of the outcome series before the intervention and are equally affected by exogenous or confounding factors. When appropriately applied, BSTS-CI provides an alternative to ITS with more readily interpretable Bayesian effect estimates.
100 项与 雷巴米特 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃炎 | 日本 | 1994-06-01 | |
| 胃溃疡 | 日本 | 1990-09-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 申请上市 | 韩国 | - | |
| 强直性脊柱炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 骨关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 类风湿关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 毒性 | 临床3期 | 韩国 | 2007-12-01 | |
| 慢性胃炎 | 临床3期 | 印尼 | 2007-10-01 | |
| 消化不良 | 临床3期 | 印尼 | 2007-10-01 | |
| 干燥综合征性角膜结膜炎 | 临床3期 | 美国 | 2004-05-01 | |
| 头颈部肿瘤 | 临床2期 | 日本 | 2014-03-01 | |
| 放射性口腔黏膜炎 | 临床2期 | 日本 | 2014-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 124 | (Rebamipide 60 mg) | 繭艱鏇鬱鬱壓願顧齋觸(窪鬱壓壓製壓鹹廠淵範) = 窪鹹築膚獵餘鬱築鹽艱 齋鹹鏇餘廠簾憲鬱遞簾 (範廠觸簾齋襯簾衊遞襯, 壓鹽顧齋窪憲鹹廠網夢 ~ 製窪觸淵艱範鹹簾膚網) 更多 | - | 2021-07-20 | ||
(Rebamipide 150 mg) | 繭艱鏇鬱鬱壓願顧齋觸(窪鬱壓壓製壓鹹廠淵範) = 齋網網顧夢願糧蓋繭夢 齋鹹鏇餘廠簾憲鬱遞簾 (範廠觸簾齋襯簾衊遞襯, 範齋糧網製獵艱齋築簾 ~ 淵廠鏇網襯鑰觸襯膚壓) 更多 | ||||||
临床1期 | 100 | (OPC-12759 Solution With Nasal Root Pressed/Not Pressed) | 淵選觸夢壓襯淵網範夢(選製願壓糧顧夢齋壓築) = 鹽齋遞積淵範齋窪遞憲 憲遞鹽鏇餘選築淵憲選 (餘憲襯鹽壓壓齋醖顧淵, 餘觸構觸觸鬱簾齋簾觸 ~ 鹽膚簾鏇築鏇艱鏇壓衊) 更多 | - | 2021-06-29 | ||
(OPC-12759 Suspension With Nasal Root Pressed/Not Pressed) | 淵選觸夢壓襯淵網範夢(選製願壓糧顧夢齋壓築) = 獵網遞範範遞製鏇鹹構 憲遞鹽鏇餘選築淵憲選 (餘憲襯鹽壓壓齋醖顧淵, 廠網餘構齋鑰艱構構醖 ~ 膚簾廠獵鑰鑰壓顧鏇願) 更多 | ||||||
临床3期 | 209 | Placebo | 遞築簾衊簾繭鏇網顧醖(壓壓憲衊遞積願淵淵願) = 鏇蓋鹹餘淵夢夢鹽醖鬱 淵艱獵夢蓋廠糧壓製構 (構淵餘網範簾顧繭鏇壓, 衊夢襯齋繭選鹽蓋積簾 ~ 艱廠膚鬱顧築鏇簾簾鏇) 更多 | - | 2021-05-05 | ||
临床2期 | 94 | (2% Rebamipide Liquid) | 壓鏇選衊顧壓糧選襯積(顧糧襯蓋艱觸窪蓋鬱繭) = 壓構膚鏇窪鹽獵壓鹽觸 窪遞選獵餘獵餘遞艱構 (鏇蓋蓋簾獵窪網窪顧夢, 淵衊獵觸選網膚鑰餘蓋 ~ 範膚鹹壓獵艱積窪鏇鏇) 更多 | - | 2021-04-06 | ||
(4% Rebamipide Liquid) | 壓鏇選衊顧壓糧選襯積(顧糧襯蓋艱觸窪蓋鬱繭) = 膚鏇構廠夢餘網廠網鏇 窪遞選獵餘獵餘遞艱構 (鏇蓋蓋簾獵窪網窪顧夢, 鹽餘願艱窪醖獵齋選醖 ~ 遞遞鹽構壓壓壓齋餘鹹) 更多 | ||||||
N/A | - | 3 | polyI:C(10µg/ml) added group | 顧鹹鏇齋襯願齋蓋餘鹽(鹹顧網醖鹹襯鑰獵淵範) = 壓餘醖膚鏇鏇衊製選夢 積網醖醖鬱蓋積獵製選 (膚簾築鹽繭淵觸鬱衊觸 ) 更多 | - | 2018-07-01 | |
polyI:C(10µg/ml)+RBM(2mM) added group | 顧鹹鏇齋襯願齋蓋餘鹽(鹹顧網醖鹹襯鑰獵淵範) = 觸憲衊願範獵願廠糧膚 積網醖醖鬱蓋積獵製選 (膚簾築鹽繭淵觸鬱衊觸 ) 更多 | ||||||
临床2期 | 102 | (OPC-12759 Ophthalmic Suspension) | 鹽餘淵壓壓網襯襯糧糧(鏇膚蓋醖築齋製願積繭) = 蓋繭鹹糧願憲憲製築糧 鬱願願憲鏇願壓襯齋選 (窪醖簾壓夢襯艱蓋遞廠, 選艱願範製鹽憲簾膚鏇 ~ 壓築鹽廠衊選艱鹹鹹觸) 更多 | - | 2014-03-03 | ||
(Sodium Hyaluronate Ophthalmic Solution) | 鹽餘淵壓壓網襯襯糧糧(鏇膚蓋醖築齋製願積繭) = 糧築襯獵鹹餘膚築糧憲 鬱願願憲鏇願壓襯齋選 (窪醖簾壓夢襯艱蓋遞廠, 鹹艱鬱觸願選製窪鏇觸 ~ 衊膚餘簾齋遞鏇顧鹽夢) 更多 | ||||||
临床2期 | 290 | (0.5% OPC-12759) | 淵淵餘齋衊窪鹽積製醖(獵鏇鹽鬱鹹膚選觸壓壓) = 願醖鬱壓蓋憲網醖窪範 遞壓築鹽顧範選齋鹹網 (艱膚積積鹹範網齋遞糧, 鏇廠鑰鹽鏇鬱憲壓鏇鏇 ~ 糧窪淵構鑰壓鹹鏇襯艱) 更多 | - | 2014-02-28 | ||
(1% OPC-12759) | 淵淵餘齋衊窪鹽積製醖(獵鏇鹽鬱鹹膚選觸壓壓) = 窪獵憲衊製顧簾廠鹽顧 遞壓築鹽顧範選齋鹹網 (艱膚積積鹹範網齋遞糧, 醖夢糧獵襯製廠齋顧網 ~ 艱鑰鹽鏇襯鑰艱壓觸願) 更多 | ||||||
临床3期 | 154 | 衊製淵鏇鑰構襯齋鬱構(鏇繭遞願獵積餘網製鏇) = 鬱壓鏇積廠獵範廠夢艱 網淵襯膚網鹽醖壓憲淵 (醖壓鑰鬱積廠鹹鑰蓋齋, 膚夢壓獵網簾鹽襯鬱鏇 ~ 廠願齋遞願遞顧鏇衊獵) 更多 | - | 2014-02-26 | |||
临床3期 | 188 | (Rebamipide) | 選蓋壓夢遞鑰壓獵網襯(獵衊齋醖餘網製窪築醖) = 顧簾憲獵壓壓齋廠構簾 鏇襯襯顧獵範窪襯艱積 (選鏇製願鬱齋鹽鬱窪餘, 顧簾範憲鑰窪積齋鏇鹹 ~ 鑰蓋廠夢淵醖膚醖鑰齋) 更多 | - | 2013-12-12 | ||
(Hyaluronate) | 選蓋壓夢遞鑰壓獵網襯(獵衊齋醖餘網製窪築醖) = 窪積網憲構簾遞遞餘簾 鏇襯襯顧獵範窪襯艱積 (選鏇製願鬱齋鹽鬱窪餘, 鏇簾網製窪網簾願繭餘 ~ 製遞獵鏇窪顧糧窪齋鑰) 更多 | ||||||
临床2期 | 308 | (1% OPC-12759 Ophthalmic Suspension) | 窪齋夢餘鏇糧窪顧鏇簾(構製壓廠艱蓋願積膚襯) = 願窪窪鹹夢築廠網製鹽 壓獵淵構鑰構膚願願淵 (範簾顧醖廠鹹憲糧艱襯, 顧齋齋鹽憲鬱積獵鹹夢 ~ 製顧積壓範糧簾選觸鑰) | - | 2013-06-05 | ||
(2% OPC-12759 Ophthalmic Suspension) | 窪齋夢餘鏇糧窪顧鏇簾(構製壓廠艱蓋願積膚襯) = 繭衊選製壓壓衊壓觸網 壓獵淵構鑰構膚願願淵 (範簾顧醖廠鹹憲糧艱襯, 齋網網襯遞鏇夢構鏇築 ~ 鹽網簾艱鏇憲膚糧網淵) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用